Association of circulating cellular adhesion molecules with menopausal status and hormone replacement therapy: Time-dependent change in transdermal, but not oral estrogen users

Thrombosis Research

Volumn 101, Issue 2, 2001, Pages 35-43

  Oger, Emmanuel ^a   Alhenc Gelas, Martine ^b   Plu Bureau, Genevieve ^a   Mennen, Louise ^a   Cambillau, Michele ^b   Guize, Louis ^c   Pujol, Yamilee ^a   Scarabin, Pierre Yves ^a  

^a HÔPITAL PAUL BROUSSE   (France)

^b HÔPITAL BROUSSAIS   (France)

^c Centre d'Investigations Preventives et Cliniques   (France)

Author keywords

Cell adhesion molecule; Hormone replacement therapy; Menopause

Indexed keywords

C REACTIVE PROTEIN; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ESTROGEN; FIBRINOGEN; INTERCELLULAR ADHESION MOLECULE 1; PADGEM PROTEIN; PROGESTERONE; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGE; ARTICLE; BODY MASS; CHRONOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES; E-SELECTIN; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MENOPAUSE; MIDDLE AGED; P-SELECTIN; TIME FACTORS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0035862634     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00382-0     Document Type: Article

References (43)

1. Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham population
2. Cardiovascular disease in women. A statement for healthcare professionals from the American Heart Association
3. Haemostatic variables and menopausal status: Influence of hormone replacement therapy
4. Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women
5. Effects of hormone replacement therapy on fibrinolysis in postmenopausal women
6. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomised controlled trial
7. The protective effects of estrogen on the cardiovascular system
8. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women
9. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women
10. Estrogen and postmenopausal estrogen/progestin therapy: Effect on endothelium-dependent prostacyclin, nitric oxide and endothelin-1 production
11. Atherosclerosis: Basic mechanisms, oxidation, inflammation, and genetics
12. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells
13. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro
14. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. The Atherosclerosis Risk In Communities (ARIC) Study
15. Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin, and thrombomudulin
16. Circulating ICAM-1 and VCAM-1 in peripheral artery disease and hypercholesterolemia: Relationship to the location of atherosclerotic disease, smoking, and in the prediction of adverse events
17. Plasma concentration of circulating intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men
18. Effects of hormone therapy on inflammatory cell adhesion molecules in postmenopausal healthy women
19. Modulation of circulating cellular adhesion molecules in postmenopausal women
20. Short-term hormone replacement therapy: Reduced plasma levels of soluble adhesion molecules
21. Hormone replacement therapy and circulating ICAM-1 in postmenopausal women. A randomised controlled trial
22. Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women
23. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogen
24. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
25. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women
26. C-reactive protein: A cardiovascular risk. Report on the CRP hot-topic workshop
27. Hormone replacement therapy, inflammation, and hemostasis in elderly women
28. Hormone replacement therapy and increased plasma concentration of C-reactive protein
29. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women
30. Effect of postmenopausal hormones on inflammation-sensitive proteins. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study
31. Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes
32. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction. A potential role for cytokines originating from adipose tissue?
33. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women. A 2-year, placebo-controlled study
34. Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion
35. Soluble vascular cell adhesion molecule-1 (VCAM-1) as potential marker of atherosclerosis
36. Gene regulation by steroid hormones
37. Down-modulation of interleukine-6 gene expression by 17β-estradiol by the estrogen receptor
38. Effects of 17β-estradiol on cytokine-induced endothelial cell adhesion molecule expression
39. Protective effect of 17β-estradiol against the cytotoxicity of minimally oxidized LDL to cultured bovine aortic endothelial cells
40. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women
41. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells
42. Vittinghoff E for the Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
43. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study